Torigen Pharmaceuticals, Inc. produces an experimental Autologous Prescription Product regulated by the USDA Center for Veterinary Biologics. For use under supervision/prescription of a licensed veterinarian. Safety and efficacy have not been established.
Torigen Pharmaceuticals, Inc. produces an experimental Autologous Prescription Product regulated by the USDA Center for Veterinary Biologics. For use under supervision/prescription of a licensed veterinarian. Safety and efficacy have not been established.
Torigen Pharmaceuticals, Inc. produces an experimental Autologous Prescription Product regulated by the USDA Center for Veterinary Biologics. For use under supervision/prescription of a licensed veterinarian. Safety and efficacy have not been established.
Torigen Pharmaceuticals, Inc. produces an experimental Autologous Prescription Product regulated by the USDA Center for Veterinary Biologics. For use under supervision/prescription of a licensed veterinarian. Safety and efficacy have not been established.
Torigen Pharmaceuticals, Inc. produces an experimental Autologous Prescription Product regulated by the USDA Center for Veterinary Biologics. For use under supervision/prescription of a licensed veterinarian. Safety and efficacy have not been established.
Ship sites with style.
Our Science
Our Science
Our Science
Get Started
Learn More
The Science of Personalized Cancer Vaccines
The Science of Personalized Cancer Vaccines
The Science of Personalized Cancer Vaccines
The Science of Personalized Cancer Vaccines
The Science of Personalized Cancer Vaccines
At Torigen, we create personalized cancer vaccines utilizing the patient's own tumor cells as our antigenic backbone. Our technology is how we capture and preserve the mutational antigens on the surface of a tumor cell. Because this therapy is produced directly from harvested tumor material, it avoids distortion of the antigenic menu that can result from in vitro culture. This allows for a variety of tumor-associated antigens to be presented to the patient’s immune system, which may increase the likelihood of a successful response.
Thousands of dogs, cats, horses and even some exotic animals have been treated with our personalized cancer vaccine to date.
At Torigen, we create personalized cancer vaccines utilizing the patient's own tumor cells as our antigenic backbone. Our technology is how we capture and preserve the mutational antigens on the surface of a tumor cell. Because this therapy is produced directly from harvested tumor material, it avoids distortion of the antigenic menu that can result from in vitro culture. This allows for a variety of tumor-associated antigens to be presented to the patient’s immune system, which may increase the likelihood of a successful response.
Thousands of dogs, cats, horses and even some exotic animals have been treated with our personalized cancer vaccine to date.
At Torigen, we create personalized cancer vaccines utilizing the patient's own tumor cells as our antigenic backbone. Our technology is how we capture and preserve the mutational antigens on the surface of a tumor cell. Because this therapy is produced directly from harvested tumor material, it avoids distortion of the antigenic menu that can result from in vitro culture. This allows for a variety of tumor-associated antigens to be presented to the patient’s immune system, which may increase the likelihood of a successful response.
Thousands of dogs, cats, horses and even some exotic animals have been treated with our personalized cancer vaccine to date.
Immunotherapy Explained
Immunotherapy
Explained
Like Torigen’s immunotherapy, cancer vaccines that utilize the patient's own tumor cell as the antigenic backbone allow for a greater variety of antigens to be presented to the immune system. The identity of individual antigens is often unknown, but it can be assumed that the rich choice of antigenic targets increases the likelihood of a successful immune response.
Research into cancer immunotherapy, more specifically the effectiveness of tissue vaccines, has culminated in the development of our product, an autologous cancer vaccine comprised of deactivated tumor cells combined with a medical-grade adjuvant, particulate small intestinal submucosa (SIS). Studies have proven the effectiveness of such a treatment in significantly decreasing cancer tumor malignancy and metastasis in clinical and pre-clinical models. The mechanism of action is currently understood to be an SIS-facilitated immune system interaction with targeted tumor cells and synergistic induction of a rejection microenvironment through a robust Th1 immune response to incite cancer immunity.
Like Torigen’s immunotherapy, cancer vaccines that utilize the patient's own tumor cell as the antigenic backbone allow for a greater variety of antigens to be presented to the immune system. The identity of individual antigens is often unknown, but it can be assumed that the rich choice of antigenic targets increases the likelihood of a successful immune response.
Research into cancer immunotherapy, more specifically the effectiveness of tissue vaccines, has culminated in the development of our product, an autologous cancer vaccine comprised of deactivated tumor cells combined with a medical-grade adjuvant, particulate small intestinal submucosa (SIS). Studies have proven the effectiveness of such a treatment in significantly decreasing cancer tumor malignancy and metastasis in clinical and pre-clinical models. The mechanism of action is currently understood to be an SIS-facilitated immune system interaction with targeted tumor cells and synergistic induction of a rejection microenvironment through a robust Th1 immune response to incite cancer immunity.
Like Torigen’s immunotherapy, cancer vaccines that utilize the patient's own tumor cell as the antigenic backbone allow for a greater variety of antigens to be presented to the immune system. The identity of individual antigens is often unknown, but it can be assumed that the rich choice of antigenic targets increases the likelihood of a successful immune response.
Research into cancer immunotherapy, more specifically the effectiveness of tissue vaccines, has culminated in the development of our product, an autologous cancer vaccine comprised of deactivated tumor cells combined with a medical-grade adjuvant, particulate small intestinal submucosa (SIS). Studies have proven the effectiveness of such a treatment in significantly decreasing cancer tumor malignancy and metastasis in clinical and pre-clinical models. The mechanism of action is currently understood to be an SIS-facilitated immune system interaction with targeted tumor cells and synergistic induction of a rejection microenvironment through a robust Th1 immune response to incite cancer immunity.
Research and
Development
at Torigen
Research and
Development
at Torigen
Research and
Development
at Torigen
Every tumor that gets submitted into Torigen is retained and utilized to further cancer research.
Cancer research is at the core of everything we do.
In addition to our personalized cancer vaccine, Torigen Pharmaceuticals has a strong research and development pipeline. Our dedication to innovative research and collaborative relationship-building allows us to leverage the veterinary field and provide novel advances in the industry.
Torigen offers a personalized cancer vaccine for dogs, cats and horses that uses the animal’s own tumor cells to create a personalized immunotherapy. It comes with a simple protocol, and can be used alone or in combination with chemotherapy and radiation for multiple cancer types. Now, you can offer a cancer treatment at an affordable price, all within your practice.
Read and download our publications below.
Torigen offers a personalized cancer vaccine for dogs, cats and horses that uses the animal’s own tumor cells to create a personalized immunotherapy. It comes with a simple protocol, and can be used alone or in combination with chemotherapy and radiation for multiple cancer types. Now, you can offer a cancer treatment at an affordable price, all within your practice.
Read and download our publications below.
Immunotherapy for Your Practice
Immunotherapy for Your Practice
